Literature DB >> 8003050

Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism.

R W Simms1, S H Roy, M Hrovat, J J Anderson, G Skrinar, S R LePoole, C A Zerbini, C de Luca, F Jolesz.   

Abstract

OBJECTIVE: To compare parameters of muscle energy metabolism in patients with fibromyalgia syndrome (FMS) and sedentary controls.
METHODS: Thirteen female FMS patients and 13 female sedentary controls underwent a standardized clinical assessment (including dolorimeter measurements of the upper trapezius and tibialis anterior muscles) and a standardized aerobic fitness test including measurement of maximum oxygen uptake (VO2max). Phosphorus (31P) magnetic resonance spectroscopy studies of the upper trapezius and tibialis anterior muscles were then performed in FMS patients and controls, at rest and during and following a muscle-fatiguing exercise protocol.
RESULTS: FMS patients and controls had similar levels of VO2max and of maximum voluntary contraction (MVC) of the upper trapezius and tibialis anterior muscles. After controlling for VO2max and MVC, measurements of phosphocreatine (PCr), inorganic phosphate (P(i)), and intracellular pH in these muscles were not significantly different in FMS patients versus sedentary controls either at rest, during exercise, or during recovery. In the patients with FMS, no correlation was found between overall or local pain severity and the principal muscle metabolic parameter, PCr/P(i). Inverse correlations between dolorimeter scores at 2 muscle sites and tibialis anterior PCr/P(i) were found both in patients and in controls.
CONCLUSION: This study demonstrates that under the conditions studied, muscle energy metabolism in FMS is no different than that in sedentary controls. These findings do not support the hypothesis that detectable defects in muscle energy metabolism occur in FMS.

Entities:  

Mesh:

Year:  1994        PMID: 8003050     DOI: 10.1002/art.1780370603

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

1.  Treatment of fibromyalgia with antidepressants: a meta-analysis.

Authors:  P G O'Malley; E Balden; G Tomkins; J Santoro; K Kroenke; J L Jackson
Journal:  J Gen Intern Med       Date:  2000-09       Impact factor: 5.128

2.  [Etiology and pathophysiology of fibromyalgia syndrome and chronic widespread pain].

Authors:  C Sommer; W Häuser; K Gerhold; P Joraschky; F Petzke; T Tölle; N Uçeyler; A Winkelmann; K Thieme
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

3.  Tissue oxygen measurement and 31P magnetic resonance spectroscopy in patients with muscle tension and fibromyalgia.

Authors:  E S Strobel; M Krapf; M Suckfüll; W Brückle; W Fleckenstein; W Müller
Journal:  Rheumatol Int       Date:  1997       Impact factor: 2.631

Review 4.  Chronic pain syndromes.

Authors:  S Carette
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 5.  Fibromyalgia: from pathophysiology to therapy.

Authors:  Tobias Schmidt-Wilcke; Daniel J Clauw
Journal:  Nat Rev Rheumatol       Date:  2011-07-19       Impact factor: 20.543

Review 6.  Fibromyalgia: why such controversy?

Authors:  D L Goldenberg
Journal:  Ann Rheum Dis       Date:  1995-01       Impact factor: 19.103

7.  Strength training induced adaptations in neuromuscular function of premenopausal women with fibromyalgia: comparison with healthy women.

Authors:  A Häkkinen; K Häkkinen; P Hannonen; M Alen
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 8.  Evidence of involvement of central neural mechanisms in generating fibromyalgia pain.

Authors:  Roland Staud
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

Review 9.  Peripheral and central sensitization in fibromyalgia: pathogenetic role.

Authors:  Roland Staud; Michael L Smitherman
Journal:  Curr Pain Headache Rep       Date:  2002-08

Review 10.  Neurobiology of fibromyalgia and chronic widespread pain.

Authors:  Kathleen A Sluka; Daniel J Clauw
Journal:  Neuroscience       Date:  2016-06-09       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.